Revvity (NYSE:RVTY) Releases Earnings Results, Beats Expectations By $0.04 EPS

Revvity (NYSE:RVTY) released its quarterly earnings results on Tuesday. The company reported $1.06 EPS for the quarter, topping the consensus estimate of $1.02 by $0.04, FiscalAI reports. Revvity had a return on equity of 7.92% and a net margin of 8.45%.The business had revenue of $711.12 million for the quarter, compared to analysts’ expectations of $704.20 million. During the same quarter in the previous year, the firm posted $1.01 earnings per share. The company’s revenue was up 7.0% compared to the same quarter last year. Revvity updated its FY 2026 guidance to 5.200-5.300 EPS.

Here are the key takeaways from Revvity’s conference call:

• Signed a letter of intent to divest the China immunodiagnostics business (≈6% of 2025 revenue), expects a definitive agreement within ~2 months and closing by end of 2027, and says the move will reweight China to ~8%–9% of revenue and boost 2026 pro forma organic growth ~100 bps and margins ~30 bps.
• Revvity beat Q1 expectations with 3% organic growth, adjusted operating margin of 23.6% and adjusted EPS of $1.06; excluding the China immunodiagnostics business, Q1 pro forma results would have been ~6% organic growth and a 24% pro forma margin.
• Software and AI are core growth drivers: the company launched Xynthetica, BioDesign, and LabGistics this year, reports SaaS/ARR growth north of 30%–40% year‑over‑year and says internal AI deployment (cited by Gartner) is accelerating product delivery and employee productivity.
• Balance sheet and cash generation remain strong — Q1 free cash flow was $115M (≈97% conversion of adjusted net income), the company repurchased $86M of stock in the quarter, finished with net leverage ~2.8x and plans to repay a ~€600M bond in July.
• Near‑term financial impact: management lowered reported 2026 adjusted EPS by roughly $0.15 to a pro forma range of $5.20–$5.30 (the guide excludes any sale proceeds), and the planned divestiture reduces previously expected 2026 revenue by ~4.5%, creating short‑term dilution and timing uncertainty until closing.

Revvity Stock Performance

NYSE:RVTY traded up $5.69 during midday trading on Tuesday, reaching $92.20. 1,042,776 shares of the company traded hands, compared to its average volume of 1,260,531. Revvity has a twelve month low of $81.22 and a twelve month high of $118.30. The firm has a market capitalization of $10.31 billion, a price-to-earnings ratio of 44.41, a price-to-earnings-growth ratio of 1.85 and a beta of 1.05. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.68 and a quick ratio of 1.40. The company has a fifty day moving average price of $90.39 and a 200 day moving average price of $96.82.

Revvity Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 7th. Investors of record on Friday, July 17th will be given a dividend of $0.07 per share. The ex-dividend date is Friday, July 17th. This represents a $0.28 dividend on an annualized basis and a yield of 0.3%. Revvity’s payout ratio is currently 13.46%.

Trending Headlines about Revvity

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Q1 results beat expectations — Revvity reported EPS of $1.06 vs. $1.02 consensus and revenue of $711.1M vs. $704.2M expected; revenue rose ~7% year‑over‑year, showing underlying demand. Revvity (RVTY) Q1 Earnings and Revenues Top Estimates
• Positive Sentiment: Business mix strength in Diagnostics and stabilization in Life Sciences noted in previews/analyst commentary — supports the beat and offers growth drivers if demand sustains. Revvity to Report Q1 Earnings: What’s in Store for the Stock?
• Neutral Sentiment: Full call transcript and slide deck posted — useful for investors who want management detail on segment trends, margins and cadence for the remainder of FY‑26. Revvity, Inc. (RVTY) Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Broker consensus is an average “Hold” — reflects mixed views: beat on the quarter but caution about guidance and near‑term demand. Revvity Inc. (NYSE:RVTY) Given Average Recommendation of “Hold” by Brokerages
• Negative Sentiment: FY‑2026 guidance was pulled back: EPS guidance of $5.20–5.30 vs. street ~5.40 and revenue guidance around $2.8B vs. ~3.0B consensus — this downgrade is the primary near‑term headwind and likely explains some sell‑side caution. View Press Release / Guidance
• Negative Sentiment: Robert W. Baird trimmed its price target to $125 (still an outperform rating) and other analysts highlight China headwinds and weaker academic demand — signals continued macro/regional risk to growth. Revvity (NYSE:RVTY) Price Target Cut to $125.00 by Analysts at Robert W. Baird

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RVTY. Schroder Investment Management Group boosted its position in Revvity by 5.0% during the 3rd quarter. Schroder Investment Management Group now owns 4,751 shares of the company’s stock worth $416,000 after acquiring an additional 225 shares during the period. Brown Brothers Harriman & Co. raised its position in shares of Revvity by 61.1% during the fourth quarter. Brown Brothers Harriman & Co. now owns 4,098 shares of the company’s stock worth $396,000 after purchasing an additional 1,554 shares during the period. Quantitative Investment Management LLC raised its position in shares of Revvity by 19.4% during the fourth quarter. Quantitative Investment Management LLC now owns 4,014 shares of the company’s stock worth $388,000 after purchasing an additional 653 shares during the period. Virtu Financial LLC acquired a new stake in shares of Revvity during the fourth quarter worth $384,000. Finally, Nomura Holdings Inc. purchased a new stake in Revvity in the 3rd quarter worth about $270,000. Institutional investors and hedge funds own 86.65% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on RVTY shares. Jefferies Financial Group raised their price objective on Revvity from $100.00 to $105.00 and gave the company a “hold” rating in a research note on Monday, February 2nd. Wells Fargo & Company raised their price objective on Revvity from $107.00 to $110.00 and gave the company an “equal weight” rating in a research note on Tuesday, February 3rd. Barclays restated an “equal weight” rating and set a $95.00 price objective (down from $118.00) on shares of Revvity in a research note on Tuesday, April 14th. Robert W. Baird lowered their price objective on Revvity from $129.00 to $125.00 and set an “outperform” rating for the company in a research note on Monday. Finally, TD Cowen restated a “hold” rating on shares of Revvity in a research note on Tuesday, February 3rd. Three research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $109.36.

About Revvity

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.